Symproic and Tecentriq drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Symproic (naldemedine tosylate) and Tecentriq (atezolizumab). Common drug interactions include anaemia among females and cholangitis sclerosing among males.

The phase IV clinical study analyzes what interactions people have when they take Symproic and Tecentriq. It is created by eHealthMe based on reports of 32 people who take the same drugs from the FDA, and is updated regularly.

What is Symproic?

Symproic has active ingredients of naldemedine tosylate. eHealthMe is studying from 1,487 Symproic users. Check the latest studies of Symproic.

What is Tecentriq?

Tecentriq has active ingredients of atezolizumab. eHealthMe is studying from 12,796 Tecentriq users. Check the latest studies of Tecentriq.

On Jul, 23, 2026

32 people who take Symproic and Tecentriq together, and have interactions are studied.

Symproic and Tecentriq drug interactions.

What are the common drug interactions of Symproic and Tecentriq, by gender? *:

female:

Anaemia (lack of blood)
Constipation
Neutrophil count decreased (less than normal number of neutrophil a type of blood cell)
Altered state of consciousness (altered state of mind)
Carotid artery stenosis (narrowing of carotid artery)
Myoclonic epilepsy (type of epilepsy with quick little jerks of the arms, shoulder, or occasionally the legs)
Seizure (abnormal excessive or synchronous neuronal activity in the brain)
Transient ischaemic attack (a transient episode of neurologic dysfunction caused by ischemia (loss of blood flow))
Alanine aminotransferase increased
Aspartate aminotransferase increased

male:

Cholangitis sclerosing (infection and obstruction of bile duct)
Interstitial lung disease
Dysphonia (speech disorder attributable to a disorder of phonation)
Guillain-barre syndrome (the body's immune system attacks its peripheral nervous system)
Nausea (feeling of having an urge to vomit)
Platelet count decreased
Pneumonia
Pneumonia aspiration (bronchopneumonia that develops due to the entrance of foreign materials into the bronchial tree)
Rash
Renal impairment (severely reduced kidney function)

What are the common drug interactions of Symproic and Tecentriq, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

Dysphonia (speech disorder attributable to a disorder of phonation)
Guillain-barre syndrome (the body's immune system attacks its peripheral nervous system)
Pyrexia (fever)
Rash
Stevens-johnson syndrome (an immune-complex-mediated hypersensitivity disorder. it ranges from mild skin and mucous membrane lesions to a severe)

50-59:

Pyrexia (fever)
Anaemia (lack of blood)
Constipation
Dysphonia (speech disorder attributable to a disorder of phonation)
Guillain-barre syndrome (the body's immune system attacks its peripheral nervous system)
Liver disorder (liver diseases)
Neutrophil count decreased (less than normal number of neutrophil a type of blood cell)
Rash
Spinal epidural haematoma (blood clot into the epidural space in the spine)
Vomiting

60+:

Cholangitis sclerosing (infection and obstruction of bile duct)
Interstitial lung disease
Carotid artery stenosis (narrowing of carotid artery)
Cerebral infarction (less blood supply to brain resulting tissue damage)
Cholangitis (infection of the bile duct)
Cytomegalovirus infection
Encephalitis (inflammation of the brain)
Myoclonic epilepsy (type of epilepsy with quick little jerks of the arms, shoulder, or occasionally the legs)
Nausea (feeling of having an urge to vomit)
Pneumonia

What are the existing conditions these people have? *

Lung Adenocarcinoma (a form of non-small cell lung cancer): 11 people, 34.38%
Lung Cancer - Non-Small Cell (lung cancer): 7 people, 21.88%
Pain: 5 people, 15.62%
Lung Cancer - Small Cell (lung cancer): 5 people, 15.62%
Constipation: 4 people, 12.50%
Non-Small Cell Lung Cancer Recurrent (type of epithelial lung cancer reoccurrence): 3 people, 9.38%
Nausea (feeling of having an urge to vomit): 3 people, 9.38%
Lung Neoplasm Malignant (cancer tumour of lung): 3 people, 9.38%
Hepatocellular Carcinoma (liver cancer): 3 people, 9.38%
Fever: 3 people, 9.38%

* Approximation only. Some reports may have incomplete information.

Do you take Symproic and Tecentriq?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously